ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

メトスクシミド

Methsuximide

HCID 6476
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
77-41-8
標準SMILES
CN1C(=O)CC(C)(c2ccccc2)C1=O
InChIKey
AJXPJJZHWIXJCJ-UHFFFAOYSA-N
分子式
C12H13NO2
平均分子量
203.24 g/mol
単同位体質量
203.09462866

概要

Methsuximide is an organic molecular entity.

名称と識別子

優先名称
Methsuximide
IUPAC
1,3-dimethyl-3-phenylpyrrolidine-2,5-dione
現地名
メトスクシミド
英語名
METHSUXIMIDE
分子式
C12H13NO2
分子量
203.24

名称と別名

METHSUXIMIDEMesuximide77-41-8Celontin1,3-dimethyl-3-phenylpyrrolidine-2,5-dioneMethsuximidMetsuccimideMesuximidummesuximidalpha-MethylphensuximideN,2-Dimethyl-2-phenylsuccinimide1,3-Dimethyl-3-phenylsuccinimide
名称をさらに表示
ペチヌチンメスクシミドセロンチンメトスクシミド1,3-ジメチル-3-フェニル-2,5-ピロリジンジオンメスキシミドメトスキシミド1,3-ジメチル-3-フェニルピロリジン-2,5-ジオンPetinutinRSYYMethsuximideMethsuximide (500 mg)
MesuximidaMetosuccimmide1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine1,3-Dimethyl-3-phenyl-pyrrolidin-2,5-dione2,5-Pyrrolidinedione, 1,3-dimethyl-3-phenyl-N-Methyl-alpha-methyl-alpha-phenylsuccinimidealpha-Methyl-alpha-phenyl N-methyl succinimidePM 396

データベース識別子

CAS
77-41-8
PubChem CID
6476
DTXSID
DTXSID5023293
ChEMBL
CHEMBL697
ChEBI
CHEBI:6846
UNII
0G76K8X6C0
EC Number
201-026-7
Nikkaji
J4.203J

物性

構造計算による物性補完中

XLogP
1.2
極性表面積
37.4 Ų
水素結合供与体数
0
水素結合受容体数
2
回転可能結合数
1
重原子数
15
形式電荷
0
複雑度
294

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals

Pharmaceuticals -> Antiepileptics

OdorOdorless to slight odor
Color/Form · 2 件

Crystals from dilute alcohol

White to grayish white, crystalline powder

Solubility · 3 件

Freely sol in methanol, alcohol

Slightly soluble in hot water; freely soluble in alcohol and ether; very soluble in chloroform.

2.13e+00 g/L

Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Boiling Point121-122 °C at 0.1 mm Hg
DecompositionWhen heated to decomposition it emits toxic fumes of /nitrogen oxides/ .
Melting Point · 2 件

52-53 °C

52.5 °C

Physical DescriptionSolid
Stability/Shelf LifeMethsuximide has a relatively low melting range (50 to 56 °C or 122 to 133 °F). Improper storage may result in melting and subsequent impaired absorption of the capsule contents. /Methsuximide Capsules USP/

物理化学的性質

融点
52 · 52-53°
沸点
0.1 · bp0.1 121-122°
比重(密度)
1.1255 · 1.1255 (rough estimate)
屈折率
1.544 · 1.5440 (estimate)
貯蔵温度
Refrigerator
溶解性
クロロホルム(微量)、メタノール(微量)
外見
個体
色
ホワイトからオフホワイト
水溶解度
2.8 g/L · 2.8g/L(25℃)

化学的性質

化学的特性Light Yellow Oil

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P273, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 41 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information2,5-Pyrrolidinedione, 1,3-dimethyl-3-phenyl-: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 2,5-Pyrrolidinedione, 1,3-dimethyl-3-phenyl-: Environment tier I assessment
FDA Requirements · 1 件

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl methsuximide, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Special Reports · 4 件

Schardein JL; Chemically Induced Birth Defects 2: 157-207 (1993). Anticonvulsant induced birth defects.

Gilstrap LC, Little BB; Drugs and Pregnancy 125-32 (1992). Anticonvulsant drugs during pregnancy.

Battino D, et al; Clin Pharmacokinet 29: 257-86 (1995). An overview of the clinical pharmacokinetics of ... methsuximide ... in pediatric patients is considered.

Briggs GG, et al; Drugs Preg Lactation 203-63 (1984). Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk.

Hazard Classes and CategoriesAcute Tox. 4 (100%)

安全と保護具

Storage ConditionsStore below 30 °C (86 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight container. Avoid exposure to excessive heat. /Methsuximide Capsules USP/
Disposal Methods · 1 件

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

毒性情報

Treatment · 1 件

Treatment should include emesis (unless the patient is or could rapidly become obtunded, comatose, or convulsing) or gastric lavage, activated charcoal, cathartics, and general supportive measures. Charcoal hemoperfusion may be useful in removing the N-desmethyl metabolite of methsuximide. Forced diuresis and exchange transfusions are ineffective. (L1712)

Interactions · 5 件

Concurrent use /with alcohol; central nervous system depression-producing medications; tricyclic antidepressants; loxapine; maprotiline; molindone; monoamine oxidase inhibitors; phenothiazines; pimozide; thioxanthenes/ may lower the convulsive threshold, enhance CNS depression, and decrease the effects of the anticonvulsant medication. /Succinimide anticonvulsants/

Requirements for folic acid may be increased in patients receiving anticonvulsant therapy. /Succinimide anticonvulsants/

Induction of hepatic microsomal enzyme activity resulting in increased metabolism and decreased serum concentrations and elimination half-lives of succinimide anticonvulsants and/or these medications /carbamazepine, phenobarbital, phenytoin, primidone/ may occur during concurrent therapy; monitoring of serum concentrations as a guide to dosage is recommended, especially when any anticonvulsant is added to or withdrawn from an existing regimen. /Succinimide anticonvulsants/

Concurrent use /with haloperidol/ may cause a change in the pattern and/or the frequency of epileptiform seizures; dosage adjustments of the anticonvulsant may be necessary; serum concentrations of haloperidol may be significantly reduced. /Succinimide anticonvulsants/

For more Interactions (Complete) data for METHSUXIMIDE (9 total), please visit the HSDB record page.

Health EffectsMay cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease.
Hepatotoxicity · 1 件

Prospective studies suggest that chronic methsuximide therapy is not accompanied by significant elevations in serum aminotransferase levels, although it has been shown to have hepatotoxicity in animals. Clinically apparent hepatotoxicity from methsuximide has not been reported, although hypersensitivity reactions with fever and rash are not uncommon (1% to 5%). The product label for methsuximide warns of hepatic dysfunction and recommends periodic liver function studies. Nevertheless, clinically apparent liver injury from methsuximide must be very rare, if it occurs at all.

Exposure RoutesOral
Toxicity Summary · 1 件

Methsuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.

Signs and SymptomsAcute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression. Levels greater than 40 µg/mL have caused toxicity and coma has been seen at levels of 150 µg/mL.
Human Toxicity Excerpts · 5 件

/SIGNS AND SYMPTOMS/ Adverse hematologic effects associated with methsuximide include eosinophilia, leukopenia, monocytosis, and pancytopenia. Adverse dermatologic effects may include urticaria, pruritic erythematous rash, and Steven-Johnson syndrome. Adverse genitourinary effects associated with methsuximide include proteinuria and microscopic hematuria. Periorbital edema and hyperemia have also occurred. Systemic lupus erythematosus has been associated with succinimide use.

/SIGNS AND SYMPTOMS/ GI disturbances such as ... diarrhea, wt loss, epigastric & abdominal pain, & constipation occur frequently. Hemopoietic complications including eosinophilia ... Monocytosis, & pancytopenia have been reported. Neurologic & sensory reactions observed including ... irritability, nervousness ... blurred vision, photophobia...and insomnia.

/SIGNS AND SYMPTOMS/ Dermatologic disturbances including urticaria, Stevens-Johnson syndrome, & pruritic erythematous rashes.

/SIGNS AND SYMPTOMS/ Drowsiness, gastrointestinal disturbance, hiccups, irritability, and headache /are/ the common side effects of methsuximide.

For more Human Toxicity Excerpts (Complete) data for METHSUXIMIDE (9 total), please visit the HSDB record page.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Methsuximide

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity Excerpts · 2 件

/LABORATORY ANIMALS: Acute Exposure/ Phensuximide (PSX), methsuximide (MSX) and ethosuximide (ESX) are succinimide antiepileptie agents used worldwide in the treatment of absence seizures. A previous study ... demonstrated that PSX (0.3 or 0.6 mmol/kg/day ip) induced urotoxicity following daily administration for 5-7 days in Fischer 344 rats, but PSX (1.25 mmol/kg, ip) induced only minimal urotoxicity following acute administration. The purpose of this study was to determine the acute nephrotoxic potential of MSX and ESX in male Fischer 344 rats and if antiepileptic succinimide induced urotoxicity is potentiated by phenobarbital pretreatment. In one set of experiments, rats (four rats per group) were administered a single ip injection of a succinimide (0.4 or 1.0 mmol/kg) or vehicle (sesame oil, 2.5 mL/kg), and the renal function was monitored at 24 and 48 hr. Neither ESX or MSX induced substantial changes in renal function or morphology, which suggests that neither compound is acutely nephrotoxic. Similar results were obtained with PSX, whiCh supported ... earlier findings with this antiepileptic agent. In a second set of experiments, rats (four rats per group) were pretreated for 3 days with phenobarbital (75 mg kg/day, ip) prior to receiving a succinimide (0.4 or 1.0 mmol/kg, ip) or vehicle (sesame oil, 2.5 mL/kg, ip). Renal function was monitored at 24 and 48 hr after the last injection. Phenobarbital pretreatment had only minor effects on ESX or MSX induced renal effects, with no significant morphological changes detected between treated and pair fed control groups.

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ ... Drugs of widely differing pharmacological activity have been administered to partially hepatectomized male rats and the extent of liver regeneration ascertained over a period of ten days. ... The following fed ad lib in diets supplemented in a basal ration at the weight percent 0.15 methsuximide ... was hepatotrophic. ...

Environmental Water Concentrations · 1 件

While data specific to methsuximide were not located(SRC, 2007), the literature suggests that some pharmaceutically active compounds originating from human and veterinary therapy are not eliminated completely in municipal sewage treatment plants and are therefore discharged into receiving waters(1). Wastewater treatment processes often were not designed to remove them from the effluent(2). Selected organic waste compounds may be degrading to new and more persistent compounds that may be released instead of or in addition to the parent compound(2).

法規制情報

FDA Requirements · 1 件

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl methsuximide, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

安全データ

毒性
LD50 orally in mice: 0.9 g/kg (Marshall, Vallance)
hs_code
2925190100
有毒物質データの
77-41-8(Hazardous Substances Data)

化学と産業

薬理情報

ATC Code · 2 件

N - Nervous system

QN - Nervous system

Pharmacodynamics · 1 件

Used in the treatment of epilepsy. Methsuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.

Mechanism of Action · 3 件

Binds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.

Succinimide anticonvulsants are thought to increase the seizure threshold and suppress the paroxysmal three-cycle-per-second spike-and-wave pattern seen with absence (petit mal) seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex. These effects may be due to direct modification of membrane function in excitable cells and/or alteration of chemically mediated neurotransmission. The specific effect of ethosuximide against absence seizures appears to be due to its ability to block T-type calcium channels at concentrations that do not affect other ion channels. /Succinimide anticonvulsants/

Inhibition of T-type Ca(2+) channels has been proposed to play a role in the therapeutic action of succinimide antiepileptic drugs. Despite the widespread acceptance of this hypothesis, recent studies using rat and cat neurons have failed to confirm inhibition of T-type currents at therapeutically relevant concentrations. The present study re-examines this issue using the three cloned human channels that constitute the T-type family: alpha 1G, alpha 1H, and alpha 1I. The cloned cDNAs were stably transfected and expressed into mammalian cells, leading to the appearance of typical T-type currents. The results demonstrate that both ethosuximide and the active metabolite of methsuximide, alpha-methyl-alpha-phenylsuccinimide (MPS), block human T-type channels in a state-dependent manner, with higher affinity for inactivated channels. In contrast, succinimide analogs that are not anticonvulsive were relatively poor blockers. The apparent affinity of MPS for inactivated states of the three channels was estimated using two independent measures: K(I) for alpha 1G and alpha 1I was 0.3 to 0.5 mM and for alpha 1H was 0.6 to 1.2 mM. T-type channels display current at the end of long pulses (persistent current), and this current was especially sensitive to block (ethosuximide IC(50) = 0.6 mM). These drugs also reduced both the size of the T-type window current region and the currents elicited by a mock low threshold spike. /The authors/ conclude that succinimide antiepileptic drugs are capable of blocking human T-type channels at therapeutically relevant concentrations.

Biological Half-Life · 4 件

1.4-2.6 hours for mesuximide and 28-38 hours for the active metabolite.

The plasma half-life of methsuximide is slightly less than 3 hours.

The clinical efficacy of ... methsuximide was studied in relation to plasma concentrations of this compound and its desmethyl metabolite. Single- and chronic-dose studies of /methsuximide/ were carried out in five patients with intractable seizures. Patients were evaluated before and during treatment by 6-hour simultaneous video and telemetered electroencephalographic recordings to characterize the seizure type and by daily determinations of plasma antiepileptic drug concentrations. ... Methsuximide had a short half-life, averaging 1.4 hours, but its desmethyl metabolite had a mean half-life of 38 hours and therefore accumulated to levels in excess of 40 micrograms per milliliter. ...

Methsuximide ... was administered for 8 wk to 26 patients with complex partial seizures refractory to phenytoin and carbamazepine and phenobarbital or primidone. A 50% or greater reduction of complex partial seizure frequency was obtained in 8 patients. ... N-desmethylmethsuximide was the principle /metabolite/ detected in plasma and had the following pharmacokinetic values: accumulation half life, 49.7 hr; time to steady state, 10.4 days; elimination half life, 72.2 hr. ...

Metabolism/Metabolites · 6 件

Limited studies in patients who have taken extremely high doses of methsuximide and one study involving a small number of patients receiving methsuximide for the management of epilepsy indicate that the drug is metabolized via N-demethylation to N-demethylmethsuximide (NDM). Profound CNS depression following methsuximide overdosage has been attributed to this metabolite, and it is probable that the anticonvulsant effects of the drug result from NDM. Overdosage of methsuccimide may follow a biphasic course; patients have awakened and relapsed into coma within 24 hours. In one study in patients receiving methsuximide chronically, the plasma concentration of NDM was 700 times greater than the simultaneous plasma concentration of methsuximide. On the basis of this one study, a tentative therapeutic plasma NDM concentration of 10-40 ug/mL has been proposed; plasma NDM concentrations exceeding 40 ug/mL have been associated with toxicity and coma has been reported at plasma NDM concentrations of 150 ug/mL.

The pharmacokinetics of methsuximide and its major metabolite 2-methyl-2-phenylsuccinimide were studied in dogs after single intravenous doses. Plasma methsuximide levels were described by a two-compartment open model, and those of the metabolite were described by a one-compartment open model. An expression was derived that describes both methsuximide and metabolite plasma levels after methsuximide administration. Excellent fits were obtained between observed data and those predicted from the model. The metabolite, 2-methyl-2-phenylsuccinimide accounted for 40% of the overall elimination of methsuximide, and the half-life of the metabolite (15 hr) was much greater than that of the parent drug (1-3.5 hr). The results suggest that pharmacological effects after methsuximide administration may be due primarily to the metabolite, which may accumulate in the body during repeated doses.

Metabolism by hepatic microsomal enzymes in dog yields n-demethyl & parahydroxyphenyl derivatives & their glucuronides. ...

Following oral admin of 1-2 g methsuximide to dogs, alpha-(p-hydroxyphenyl)-alpha-methylsuccinimide & n-methyl-alpha-(p-hydroxyphenyl)-alpha-methylsuccinimide isolated from 48 hr urine as major metab & alpha-methyl-alpha-phenylsuccinimide as minor. No parent drug found.

Metab, n-desmethylmethsuximide level higher in phensuximide than methsuximide treated patients. Plasma elimination was 32 & 1-2 hr.

Half Life: 1.4-2.6 hours for mesuximide and 28-38 hours for the active metabolite.

FDA Pharmacological Classification · 6 件

0G76K8X6C0

METHSUXIMIDE

Established Pharmacologic Class [EPC] - Anti-epileptic Agent

Physiologic Effects [PE] - Decreased Central Nervous System Disorganized Electrical Activity

Methsuximide is an Anti-epileptic Agent. The physiologic effect of methsuximide is by means of Decreased Central Nervous System Disorganized Electrical Activity.

METHSUXIMIDE

MeSH Pharmacological ClassificationDrugs used to prevent SEIZURES or reduce their severity.
Absorption, Distribution and Excretion · 5 件

Methsuximide is absorbed from the GI tract and peak plasma concentrations are achieved in 1-3 hours. In one study, mean peak serum concentrations were 3 ug/mL following a single 600-mg dose and 6-7 ug/mL following a single 1.2-g dose of methsuximide.

Methsuximide is rapidly absorbed & metabolized. It is not bound significantly to plasma proteins.

Methsuximide is rapidly distributed throughout body after.../oral/ doses to rats, &.../it/ freely crosses blood-brain barrier.

Succinimide anticonvulsants are freely distributed to all body tissues, except fat.

For more Absorption, Distribution and Excretion (Complete) data for METHSUXIMIDE (7 total), please visit the HSDB record page.

Cellular LocationsMembrane

用途と製造

Uses · 5 件

Anticonvulsant

Anticonvulsant succinimide

MEDICATION

Use (kg; approx.) in Germany (2009): >100

For the control of absence (petit mal) seizures that are refractory to other drugs.

Methods of Manufacturing · 3 件

2-methyl-2-phenylsuccinic acid is dissolved in excess of 40% methylamine. Water & excess amine are distilled off & residue consisting of di(methylamine) salt of acid is pyrolized at about 250 °C until no more distillate is formed. Residue of crude methsuximide may be purified by vacuum dist or by...precipitation...

Prepd by action of methylamine on alpha-methyl-alpha-phenylsuccinic acid.

Acetophenone + ethyl cyanoacetate + hydrogen cyanide + methylamine (Cope reaction/addition/nitrile hydrolysis/decarboxylation/amide formation).

Formulations/Preparations · 5 件

CELONTIN

MESUXIMIDE

MESUXIMIDUM

METHSUXIMID

For more Formulations/Preparations (Complete) data for METHSUXIMIDE (6 total), please visit the HSDB record page.

応用分野 · 2 件

説明Methsuximide is a succinimide that is converted to N-desmethylmethosuximide, a channel blocker that targets low threshold calcium currents. Methsuximide is a substrate of cytochrome P450 (CYP) isoform 2C19 that, in turn, inhibits CYP2C19-mediated metabolism of biguanides. Methsuximide has been shown to have anticonvulsant properties in clinical trials.

使用A calcium channel succinimide antiepileptic drug. Anticonvulsant.

上流・下流製品情報

上流原料

メチルアミン3-メチル-3-フェニルピロリジン-2,5-ジオンヨードメタン

関連反応

0 件
反応記録を作成
関連する反応はまだありません

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート